Biotech News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ir.olema.com2026-05-04 20:35 EST
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that